LAB
BEARISH
$0.89
Live
Standard BioTools Inc. · NASDAQ
Target $1.55
(+75.1%)
$0.87
52W Range
$1.72
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$345.33M
P/E
N/A
ROE
-13.1%
Profit margin
-87.8%
Debt/Equity
0.07
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
90%
Standard BioTools (LAB) exhibits severe operational distress, highlighted by a Piotroski F-Score of 0/9, indicating a total failure across all fundamental health benchmarks. While the company maintains a strong liquidity position with a Current Ratio of 4.19 and very low debt (D/E 0.07), these are offset by catastrophic profitability metrics and a sharp Q/Q revenue decline of 49.07%. The stock is currently trading near its 52-week low, reflecting a persistent bearish technical trend and a 5-year value erosion of over 80%. Despite a low Price-to-Book ratio of 0.72, the lack of revenue growth and deep operating losses suggest a value trap rather than a bargain.
Key Strengths
Very low Debt-to-Equity ratio (0.07)
Strong short-term liquidity (Current Ratio 4.19)
Healthy Gross Margin (49.86%)
Trading below book value (P/B 0.72)
Recent EPS surprises have been positive relative to low expectations
Key Risks
Extreme operational inefficiency (Operating Margin -92.14%)
Severe revenue contraction (Q/Q growth -49.07%)
Piotroski F-Score of 0/9 indicates critical fundamental weakness
Persistent long-term price decline (5Y Change -80.7%)
Negative forward P/E indicating continued expected losses
AI Fair Value Estimate
Based on comprehensive analysis
$1.05
+18.6% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
16
Weak
35
15
10
20
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 0/9, Revenue collapse, Negative operating margins, Strong balance sheet liquidity
Confidence
95%
Value
35/100
Trading at a discount to book value, but valuation is skewed by lack of profitability.
Positives
- P/B ratio of 0.72 suggests assets are undervalued
Watchpoints
- P/S ratio of 4.05 is high for a company with negative growth
- No Graham Number due to lack of earnings
Future
15/100
Growth metrics are trending sharply downward.
Positives
- Recent Q/Q EPS growth is positive
Watchpoints
- YoY Revenue growth is negative (-4%)
- Q/Q Revenue growth is crashing (-49.07%)
Past
10/100
Long-term historical performance is overwhelmingly negative.
Positives
- Occasional earnings beats
Watchpoints
- 5-year price return of -80.7%
- Consistent history of negative earnings
Health
20/100
Balance sheet is solvent, but the business model is fundamentally unhealthy.
Positives
- Low debt levels
- High current ratio
Watchpoints
- Piotroski F-Score 0/9
- Negative ROE and ROA
Dividend
0/100
Non-dividend paying growth/speculative stock.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$0.89
Analyst Target
$1.55
Upside/Downside
+75.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LAB and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LAB
Standard BioTools Inc.
Primary
|
-80.7% | -51.6% | -19.1% | -30.5% | -8.2% | -2.2% |
|
KROS
Keros Therapeutics, Inc.
Peer
|
-80.9% | -70.2% | -8.5% | -28.6% | -0.6% | -6.6% |
|
CLLS
Cellectis S.A.
Peer
|
-83.4% | +71.4% | +189.7% | -12.0% | -6.7% | +6.0% |
|
DCTH
Delcath Systems, Inc.
Peer
|
-28.7% | +68.5% | -11.4% | -10.5% | +6.0% | +4.2% |
|
AMRN
Amarin Corporation plc
Peer
|
-88.3% | -51.5% | +87.1% | +2.2% | +1.5% | +9.1% |
LAB
Standard BioTools Inc.
Primary
5Y
-80.7%
3Y
-51.6%
1Y
-19.1%
6M
-30.5%
1M
-8.2%
1W
-2.2%
KRO
Keros Therapeutics, Inc.
Peer
5Y
-80.9%
3Y
-70.2%
1Y
-8.5%
6M
-28.6%
1M
-0.6%
1W
-6.6%
CLL
Cellectis S.A.
Peer
5Y
-83.4%
3Y
+71.4%
1Y
+189.7%
6M
-12.0%
1M
-6.7%
1W
+6.0%
DCT
Delcath Systems, Inc.
Peer
5Y
-28.7%
3Y
+68.5%
1Y
-11.4%
6M
-10.5%
1M
+6.0%
1W
+4.2%
AMR
Amarin Corporation plc
Peer
5Y
-88.3%
3Y
-51.5%
1Y
+87.1%
6M
+2.2%
1M
+1.5%
1W
+9.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-29.51
PEG Ratio
N/A
P/B Ratio
0.72
P/S Ratio
4.05
EV/Revenue
2.21
EV/EBITDA
-2.29
Market Cap
$345.33M
Profitability
Profit margins and return metrics
Profit Margin
-87.77%
Operating Margin
-92.14%
Gross Margin
49.86%
ROE
-13.13%
ROA
-9.88%
Growth
Revenue and earnings growth rates
Revenue Growth
-4.0%
Earnings Growth
N/A
Q/Q Revenue Growth
-49.07%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.07
Low debt
Current Ratio
4.19
Strong
Quick Ratio
1.86
Excellent
Cash/Share
$0.48
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
47.8%
Op. Margin
-92.1%
Net Margin
81.0%
Total Assets
$0.6B
Liabilities
$0.1B
Equity
$0.4B
Debt/Equity
0.34x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
140%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-24
$0.05
+171.4% surprise
2025-11-04
$-0.04
-101.5% surprise
2025-08-11
$-0.05
+44.4% surprise
Healthcare Sector Comparison
Comparing LAB against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
Return on Equity (ROE)
-13.13%
This Stock
vs
-49.88%
Sector Avg
-73.7%
(Below Avg)
Profit Margin
-87.77%
This Stock
vs
-9.43%
Sector Avg
+830.4%
(Superior)
Debt to Equity
0.07
This Stock
vs
3.74
Sector Avg
-98.1%
(Less Debt)
Revenue Growth
-4.0%
This Stock
vs
80.78%
Sector Avg
-105.0%
(Slower)
Current Ratio
4.19
This Stock
vs
3.72
Sector Avg
+12.7%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LAB
Standard BioTools Inc.
|
BEARISH | $345.33M | - | -13.1% | -87.8% | $0.89 | |
|
KROS
Keros Therapeutics, Inc.
|
NEUTRAL | $341.37M | 4.87 | 19.9% | 35.7% | $11.21 | Compare |
|
CLLS
Cellectis S.A.
|
BEARISH | $337.99M | - | -65.3% | -84.9% | $3.36 | Compare |
|
DCTH
Delcath Systems, Inc.
|
NEUTRAL | $336.0M | 138.14 | 3.0% | 3.2% | $9.67 | Compare |
|
AMRN
Amarin Corporation plc
|
BEARISH | $319.13M | - | -8.2% | -18.2% | $15.34 | Compare |
LAB
Standard BioTools Inc.
BEARISH
Mkt Cap
$345M
P/E
-
ROE
-13.1%
Price
$0.89
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-06 | KIM HANJOON ALEX | Chief Financial Officer | Stock Award | 70,183 | - |
| 2026-04-06 | EGHOLM MICHAEL | Chief Executive Officer | Stock Award | 196,513 | - |
| 2026-03-20 | MACKAY SEAN | Officer | Stock Award | 272,107 | - |
| 2026-03-20 | KIM HANJOON ALEX | Chief Financial Officer | Stock Award | 323,173 | - |
| 2026-03-20 | EGHOLM MICHAEL | Chief Executive Officer | Stock Award | 1,042,373 | - |
| 2026-02-26 | COX TROY M | Director | Stock Award | 57,264 | $66,999 |
| 2026-02-26 | CASDIN ELI | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award | 52,991 | $61,999 |
| 2026-02-26 | CAREY THOMAS D | Director | Stock Award | 51,282 | $60,000 |
| 2025-12-04 | CASDIN PARTNERS MASTER FUND, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 350,000 | $502,570 |
| 2025-11-25 | CASDIN PARTNERS MASTER FUND, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 7,700,000 | $10,053,280 |
| 2025-11-20 | CASDIN PARTNERS MASTER FUND, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 1,075,000 | $1,374,575 |
| 2025-11-17 | CASDIN PARTNERS MASTER FUND, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 925,000 | $1,126,775 |
| 2025-11-12 | CASDIN PARTNERS MASTER FUND, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | 1,175,000 | $1,379,318 |
KIM HANJOON ALEX
Chief Financial Officer
2026-04-06
70,183 shares
EGHOLM MICHAEL
Chief Executive Officer
2026-04-06
196,513 shares
MACKAY SEAN
Officer
2026-03-20
272,107 shares
KIM HANJOON ALEX
Chief Financial Officer
2026-03-20
323,173 shares
EGHOLM MICHAEL
Chief Executive Officer
2026-03-20
1,042,373 shares
COX TROY M
Director
2026-02-26
57,264 shares
·
$66,999
CASDIN ELI
Director and Beneficial Owner of more than 10% of a Class of Security
2026-02-26
52,991 shares
·
$61,999
CAREY THOMAS D
Director
2026-02-26
51,282 shares
·
$60,000
CASDIN PARTNERS MASTER FUND, L.P.
Beneficial Owner of more than 10% of a Class of Security
2025-12-04
350,000 shares
·
$502,570
CASDIN PARTNERS MASTER FUND, L.P.
Beneficial Owner of more than 10% of a Class of Security
2025-11-25
7,700,000 shares
·
$10,053,280
CASDIN PARTNERS MASTER FUND, L.P.
Beneficial Owner of more than 10% of a Class of Security
2025-11-20
1,075,000 shares
·
$1,374,575
CASDIN PARTNERS MASTER FUND, L.P.
Beneficial Owner of more than 10% of a Class of Security
2025-11-17
925,000 shares
·
$1,126,775
CASDIN PARTNERS MASTER FUND, L.P.
Beneficial Owner of more than 10% of a Class of Security
2025-11-12
1,175,000 shares
·
$1,379,318
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
2 analysts
TD Cowen
2025-11-05
Hold
Hold
Past News Coverage
Recent headlines mentioning LAB from our newsroom.
Newest → oldest
No matching news yet.